Chronic Urticaria
Chronic Urticaria is a condition characterized by the presence of itchy hives or welts on the skin that persist for six weeks or longer. It can occur spontaneously or be triggered by specific factors.
Chronic Urticaria: Testing Remibrutinib
We are exploring whether remibrutinib can help adults with Chronic Urticaria manage their symptoms better than a placebo. The study also looks at the safety of this new treatment and its effects on quality of life.
≤3 months≤5 visitsEfficacy phase (II)Partially RemoteInvestigational MedicinesOralAllergologyDermatology
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have a confirmed diagnosis of CINDU or CSU that is not well controlled with standard treatments?
- Are you currently experiencing symptoms that are bothersome to you, rated 3 or higher on a scale of 0 to 10?
- Do you have any ongoing infections, such as tuberculosis or HIV?
- Have you taken any BTK-inhibitors like remibrutinib in the last 4 months?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Lou064
Remibrutinib
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Hopital Tenon
1301:Dermatology & Allergy
Bagnolet, France
Centre Hospitalier Universitaire Grenoble Alpes
1303:Internal Medicine & Clinical Immunology Outpatient
La Tronche, France
Centre Hospitalier Universitaire De Montpellier
1302:Dermatology
Montpellier, France
Sponsor: Novartis Pharma AG
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.